Page last updated: 2024-11-04

sulfasalazine and Gastritis

sulfasalazine has been researched along with Gastritis in 3 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.

Research Excerpts

ExcerptRelevanceReference
"The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial."2.84Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Quach, LT1
Chang, BH1
Brophy, MT1
Soe Thwin, S1
Hannagan, K1
O'Dell, JR1
Parente, F1
Molteni, P1
Bollani, S1
Maconi, G1
Vago, L1
Duca, PG1
Rembacken, B1
Axon, AT1
Bianchi Porro, G1
Winney, RJ1
Gilmour, HM1
Matthews, JD1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275]353 participants (Actual)Interventional2007-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean 48-week Change in DAS28

"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment

Interventionunits on a scale (Mean)
Triple-2.12
Etanercept-2.29

Trials

1 trial available for sulfasalazine and Gastritis

ArticleYear
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
    Rheumatology (Oxford, England), 2017, 03-01, Volume: 56, Issue:3

    Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner

2017

Other Studies

2 other studies available for sulfasalazine and Gastritis

ArticleYear
Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching.
    Scandinavian journal of gastroenterology, 1997, Volume: 32, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Disease; Cross-Sectional

1997
Prednisolone in giant hypertrophic gastritis (Menetrier's disease).
    The American journal of digestive diseases, 1976, Volume: 21, Issue:4

    Topics: Aged; Bronchitis; Colitis, Ulcerative; Edema; Gastritis; Humans; Hypertrophy; Male; Prednisolone; Pr

1976